YOU ARE ABOUT TO EXIT A US HEMANEXT CORPORATE WEBSITE FOR A GLOBAL HEMANEXT ONE PRODUCT WEBSITE
Please be aware that the website you have requested is intended for the residents of countries in the European Union. The site may contain information on products or uses of those products that are not cleared, approved, or otherwise authorized in all countries or regions, including the US Food & Drug Administration.
WITH DO YOU WISH TO CONTINUE AND EXIT THIS WEBSITE?
Sickle Cell Disease Association of America, Inc. and Hemanext® Inc. Form New Strategic Partnership New alliance designed to enhance the lives of people living with sickle cell disease HANOVER, Md. and LEXINGTON, Mass., May 6, 2020 Sickle Cell Disease Association of...
PURPOSE Hemanext is committed to conducting honest, truthful, and reverent research activities, which are consistent with its Mission Statement. Hemanext assures objectivity of its research by maintaining that its Public Health Service (“PHS”), including the National...
Hemanext Announces CE Mark Submission for the HEMANEXT ONE Red Blood Cell Processing System Regulatory filing is a major step toward commercialization of transfusion-medicine innovation LEXINGTON, Mass., November 1, 2019 Hemanext Inc., a privately held medical...
Hemanext to Present Extensive, Significant Red Blood Cell Data at AABB 2019 AABB accepted all eight research abstracts for presentation at annual conference October 3, 2019 Hemanext, a privately held medical technology company dedicated to creating a world with fewer...
Hemanext will be exhibiting at the upcoming Remote Damage Control Resuscitation (RDCR) Symposium, taking place June 23 – 26, 2019 in Osøyro, Norway. The RDCR Symposium is organized by THOR – The Hemostasis and Oxygen Research Network. THOR is an international...
